Efectul osteoprotector al simvastatinei prin prisma studiilor spectroscopice în VIS-IR (original) (raw)

Medic.ro, 2020

Abstract

Introduction. Osteoporosis and dyslipidemia are two patho­logical conditions that commonly occur together, given the common risk factors. This is why it is important not only to choose the appropriate medication that does not have negative side effects on the comorbidities, but when possible, to choose a medication which may bring benefits for many pathologies. Dyslipidemia responds well to hypolipidemic medication, and data from literature show that simvastatin, in addition to the hypolipidemic ef­fect, has also a beneficial effect on bone metabolism. Aim. The purpose of this study is to evaluate the effects of simvastatin on bone healing, respectively the correlation of these effects with the literature data. Materials and method. The study was performed on rats divided into two groups, ovarectomized and neovarectomized, each in turn having two groups, control and treated with sim­va­sta­tin. Calus evaluation was performed using VIS-nearIR spectrometry to examine hematoxiline eosine (HE) his­to­lo­gi­cal stained preparations at different post-frac­ture periods, respectively 2, 4, 6 and 8 weeks. Results. We observed a decrease of the osteogenic potential in the groups of ovarectomized rats compared to the neo­va­rec­to­mized ones. At the same time, it was also observed an increased osteogenic potential in the groups treated with simvastatin compared with the control group within the group of ovarectomized rats. Conclusions. The difference in osteogenic potential between the two groups underscores the importance of estrogen in the bone healing process. Simvastatin plays a beneficial role in the process of osteogenesis, given the difference between the treated and untreated groups in each group of rats.

Radu Fechete hasn't uploaded this paper.

Let Radu know you want this paper to be uploaded.

Ask for this paper to be uploaded.